Human variability and noncancer risk assessment - An analysis of the default uncertainty factor

被引:189
作者
Renwick, AG
Lazarus, NR
机构
[1] Univ Southampton, Clin Pharmacol Grp, Southampton SO16 7PX, Hants, England
[2] Open Univ, SE Reg, E Grinstead AH19 1ES, W Sussex, England
关键词
uncertainty factor; human variability; toxicokinetics; toxicodynamics; interindividual differences;
D O I
10.1006/rtph.1997.1195
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
A 10-fold uncertainty factor is used for noncancer risk assessments to allow for possible interindividual differences between humans in the fate of the chemical in the body (kinetics) and target organ sensitivity (dynamics). Analysis of a database on the variability in each of these aspects is consistent with an even subdivision of the 10-fold factor into 10(0.5) (3.16) for kinetics and 10(0.5) (3.16) for dynamics. Analysis of the number of subjects in a normally and log-normally distributed population which would not be covered by factors of 3.16 supports this subdivision and also the use of a 10-fold factor to allow for both aspects. Analysis of kinetic data for subgroups of the population indicates that the standard default value of 3.16 for kinetics will not be adequate for all routes of elimination and all groups of the population. A scheme is proposed which would allow the selection of appropriate default uncertainty factors based on knowledge of the biological fate and effects of the chemical under review. (C) 1998 Academic Press.
引用
收藏
页码:3 / 20
页数:18
相关论文
共 142 条
[51]   PHARMACODYNAMIC MODEL OF THE HEMODYNAMIC-EFFECTS OF PINACIDIL IN NORMOTENSIVE VOLUNTEERS [J].
GIRARD, P ;
SAUMET, JL ;
DUBOIS, F ;
BOISSEL, JP .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (02) :177-182
[52]   PHARMACOKINETICS OF METOCLOPRAMIDE INTRAVENOUSLY AND ORALLY DETERMINED BY LIQUID-CHROMATOGRAPHY [J].
GRAFFNER, C ;
LAGERSTROM, PO ;
LUNDBORG, P ;
RONN, O .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 8 (05) :469-474
[53]   INTERINDIVIDUAL AND INTRAINDIVIDUAL VARIABILITY IN THE CONCENTRATION-EFFECT (SEDATION) RELATIONSHIP OF FLUNITRAZEPAM [J].
GRAHNEN, A ;
WENNERLUND, P ;
DAHLSTROM, B ;
ECKERNAS, SA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (01) :89-92
[54]   MOCLOBEMIDE, A SUBSTRATE OF CYP2C19 AND AN INHIBITOR OF CYP2C19, CYP2D6, AND CYP1A2 - A PANEL STUDY [J].
GRAM, LF ;
GUENTERT, TW ;
GRANGE, S ;
VISTISEN, K ;
BROSEN, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (06) :670-677
[55]   PHARMACOKINETICS OF TEMAFLOXACIN IN HUMANS AFTER SINGLE ORAL DOSES [J].
GRANNEMAN, GR ;
CARPENTIER, P ;
MORRISON, PJ ;
PERNET, AG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (03) :436-441
[56]   PHARMACOKINETIC AND ELECTROENCEPHALOGRAPHIC STUDY OF INTRAVENOUS DIAZEPAM, MIDAZOLAM, AND PLACEBO [J].
GREENBLATT, DJ ;
EHRENBERG, BL ;
GUNDERMAN, J ;
LOCNISKAR, A ;
SCAVONE, JM ;
HARMATZ, JS ;
SHADER, RI .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :356-365
[57]   AGE, SEX, AND NITRAZEPAM KINETICS - RELATION TO ANTIPYRINE DISPOSITION [J].
GREENBLATT, DJ ;
ABERNETHY, DR ;
LOCNISKAR, A ;
OCHS, HR ;
HARMATZ, JS ;
SHADER, RI .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (06) :697-703
[58]  
GRIENSVEN JMT, 1995, CLIN PHARMACOL THER, V58, P631
[59]   REMOXIPRIDE - A NEW POTENTIAL ANTIPSYCHOTIC COMPOUND - TOLERABILITY AND PHARMACOKINETICS AFTER SINGLE ORAL AND INTRAVENOUS ADMINISTRATION IN HEALTHY MALE-VOLUNTEERS [J].
GRIND, M ;
NILSSON, MI ;
NILSSON, L ;
OXENSTIERNA, G ;
SEDVALL, G ;
WAHLEN, A .
PSYCHOPHARMACOLOGY, 1989, 98 (03) :304-309
[60]   PHASE-I TRIAL OF TRIMETREXATE GLUCURONATE ON A 5-DAY BOLUS SCHEDULE - CLINICAL-PHARMACOLOGY AND PHARMACODYNAMICS [J].
GROCHOW, LB ;
NOE, DA ;
DOLE, GB ;
ROWINSKY, EK ;
ETTINGER, DS ;
GRAHAM, ML ;
MCGUIRE, WP ;
DONEHOWER, RC .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (02) :124-130